Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis announced positive FDA pre-IND feedback for Privosegtor, supporting a regulatory pathway for acute multiple sclerosis relapses. The feedback confirms existing data can be cross-referenced for a new IND submission planned for Q4 2026, eliminating the need for additional preclinical studies.
Key figures
- Drug Name
- Privosegtor
- Dose
- 3mg/kg daily for 5 days
- Ms prevalence us
- 850,000
- Primary endpoint
- 3 months
- Ind submission timing
- Q4 2026
- Ms relapses annual us
- 170,000
- Ms prevalence worldwide
- 2.8 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.